"Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study" by Nicholas Thatcher

Selected Works of Jerome Goldschmidt, MD

Article

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research (2019)

Nicholas Thatcher, The Christie Hospital, Manchester, United Kingdom.
Jerome H. Goldschmidt, Oncology and Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, Virginia.
Michael Thomas, University Hospital Heidelberg
Michael Schenker, Centrul de Oncologie Sf Nectarie, Craiova, Romania.
Zhiying Pan, Amgen
Luis Paz-Ares Rodriguez, Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
Valery Breder, Department of Clinical Biotechnologies, N. N. Blokhin National Medical Research Center of Oncology, Russia.
Gyula Ostoros, Koranyi National Institute for TB and Pulmonology, Budapest, Hungary.
Vladimir Hanes, Amgen

Link

Disciplines

Publication Date

January 7, 2019

DOI

10.1158/1078-0432.CCR-18-2702

Citation Information

Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, et al.. "Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study" Clinical Cancer Research Vol. 25 Iss. 7 (2019) p. 2088 - 2095
Available at: http://works.bepress.com/jerome-goldschmidt/18/